MOR - MorphoSys AG

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
27.63
-0.70 (-2.47%)
As of 12:33PM EST. Market open.
Stock chart is not supported by your current browser
Previous Close28.33
Open28.23
Bid27.18 x 100
Ask27.63 x 300
Day's Range27.44 - 28.23
52 Week Range21.75 - 35.90
Volume8,417
Avg. Volume42,239
Market Cap3.487B
Beta (3Y Monthly)1.14
PE Ratio (TTM)N/A
EPS (TTM)-0.79
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • ACCESSWIRE9 days ago

    DGAP-News: MorphoSys AG Announces Third Quarter 2018 Results

    -Advancing Proprietary Pipeline; Solid Progress in Partnered Programs -Conference Call and Webcast (in English) to be Held on November 6, 2018, at 2:00pm CET (1:00pm GMT / 8:00am EST) PLANEGG/MUNICH, GERMANY ...

  • ACCESSWIRE13 days ago

    MorphoSys to Present Data on Investigational Drugs MOR208 and MOR202 in Various Blood Cancer Indications at ASH 2018 Meeting

    - MOR208 (L-MIND): Interim data from phase 2 L-MIND study of MOR208 plus lenalidomide in 81 patients with relapsed/refractory DLBCL accepted for oral presentation - MOR208 (COSMOS): First data from exploratory ...

  • ACCESSWIRE24 days ago

    MorphoSys's Licensing Partner GSK has Reported Data on GSK3196165 from Phase 2 Study in Rheumatoid Arthritis to be Presented at the ACR Conference

    NASDAQ: MOR) announced today that, in a press release issued today, its licensing partner GSK reported data from their phase 2 BAROQUE clinical study of GSK3196165 (formerly MOR103) in rheumatoid arthritis (RA). Based on its technological leadership in generating antibodies, MorphoSys, together with its partners, has developed and contributed to the development of more than 100 product candidates, of which 29 are currently in clinical development.

  • ACCESSWIRE26 days ago

    MorphoSys's Licensee Janssen has Reported That New Tremfya(R) (Guselkumab) 3-Year Data Shows Stably Maintained Rates of Skin Clearance in Patients with Moderate to Severe Plaque Psoriasis

    MorphoSys's Licensee Janssen has Reported That New Tremfya (R) (Guselkumab) 3-Year Data Shows Stably Maintained Rates of Skin Clearance in Patients with Moderate to Severe Plaque Psoriasis PLANEGG/MUNICH, ...

  • ACCESSWIRE2 months ago

    MorphoSys to Present at Upcoming Investor Conferences

    PLANEGG and MUNICH, GERMANY / ACCESSWIRE / September 27, 2018 / MorphoSys AG (FSE: MOR; Prime Standard Segment, MDAX & TecDAX; NASDAQ: MOR) will present at the following conferences: Leerink Partners Roundtable ...

  • ACCESSWIRE2 months ago

    MorphoSys Announces its Licensee Janssen has Initiated a Phase 3 Trial (PROTOSTAR) to Evaluate Guselkumab in Pediatric Psoriasis Patients

    NASDAQ: MOR) announced today that its licensee Janssen Research & Development, LLC, has initiated a phase 3 clinical trial of guselkumab in pediatric patients suffering from chronic plaque psoriasis. According to clinicaltrials.gov, the trial, PROTOSTAR, is expected to enroll approximately 125 children between 6 and 18 years of age with plaque psoriasis and will evaluate the efficacy, safety and pharmacokinetics of guselkumab against etanercept and placebo.

  • Business Wire2 months ago

    LEO Pharma and MorphoSys Expand Strategic Alliance to Develop Peptide-derived Therapeutics

    NASDAQ: MOR) today announced an expansion of their existing strategic alliance to include peptide-derived therapeutics. The objective of the alliance is to identify novel, peptide-derived therapeutics for unmet medical needs that will be valuable additions to both companies’ pipelines. This alliance expands the existing partnership of the two companies signed in November 2016 to jointly discover and develop antibody-based therapies in dermatology.

  • ACCESSWIRE2 months ago

    MorphoSys and LEO Pharma Expand Strategic Alliance to Develop Peptide-derived Therapeutics

    NASDAQ: MOR) today announced an expansion of their existing strategic alliance to include peptide-derived therapeutics. The objective of the alliance is to identify novel, peptide-derived therapeutics for unmet medical needs that will be valuable additions to both companies' pipelines. This alliance expands the existing partnership of the two companies signed in November 2016 to jointly discover and develop antibody-based therapies in dermatology.

  • ACCESSWIRE2 months ago

    MorphoSys and Galapagos Announce Start of a Phase 1 Subcutaneous Bridging Study with MOR106

    NASDAQ: MOR) and Galapagos NV (GLPG) announced today the initiation of a phase 1 bridging study testing a subcutaneous formulation of MOR106, an investigational antibody directed against IL-17C. This bridging study is a parallel-design phase 1 clinical trial conducted in two parts. Part 2 is a multiple center, randomized, placebo-controlled, multiple dose study in patients with moderate to severe atopic dermatitis who will be treated subcutaneously for 12 weeks.

  • ACCESSWIRE2 months ago

    MorphoSys Announces That its Licensee Janssen has Reported That Tremfya(R) Improves Long-Term Patient-Reported Outcomes in Patients with Moderate to Severe Plaque Psoriasis

    NASDAQ: MOR) announced today that its licensee Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen) has announced new data that, according to a press released issued by Janssen on September 12, 2018, show clinically relevant improvements in long-term patient-reported outcomes (PRO) in patients with plaque psoriasis switched to Tremfya (R) (guselkumab) after an initial inadequate response to Humira(R) (adalimumab). Tremfya(R) is a fully human anti-IL-23 monoclonal antibody developed by Janssen, and was generated utilizing MorphoSys's proprietary HuCAL technology.

  • ACCESSWIRE2 months ago

    MorphoSys and Galapagos Announce U.S. Antitrust Clearance for Global License Agreement for MOR106 with Pharma Partner

    PLANEGG/MUNICH, GERMANY and MECHELEN, BELGIUM / ACCESSWIRE / September 12, 2018 / MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; NASDAQ: MOR) and Galapagos NV (GLPG) announced today the expiration ...

  • ACCESSWIRE2 months ago

    MorphoSys AG To Be Listed In MDAX

    PLANEGG and MUNICH, GERMANY / ACCESSWIRE / September 6, 2018 / MorphoSys AG (FSE: MOR); (XETRA: MOR) (Prime Standard Segment, TecDAX); (NASDAQ: MOR) announced today that its shares will be included in ...

  • ACCESSWIRE3 months ago

    MorphoSys to Present at Upcoming Investor Conferences

    PLANEGG and MUNICH, GERMANY / ACCESSWIRE / August 21, 2018 / MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; NASDAQ: MOR) will present at the following conferences: Commerzbank Sector Conference ...

  • ACCESSWIRE3 months ago

    DGAP-News: MorphoSys and I-Mab Biopharma Announce China IND Submission of TJ202/MOR202

    NASDAQ: MOR) and I-Mab Biopharma ("I-Mab"), a Shanghai-based biotech company focused on innovative biologics in oncology and autoimmune diseases, announced today that I-Mab has submitted an investigational new drug (IND) application to China National Drug Administration (CNDA) for TJ202/MOR202, a human monoclonal antibody directed against CD38 for the treatment of multiple myeloma. Multiple myeloma is the second most common blood cancer worldwide. The patient number has gradually increased in China in recent years due to an increasingly aging population.

  • ACCESSWIRE3 months ago

    MorphoSys AG to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 2, 2018 / MorphoSys AG (NASDAQ: MOR ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 2, 2018 at 8:00 AM Eastern Time. To listen ...

  • ACCESSWIRE3 months ago

    MorphoSys AG Reports Second Quarter 2018 Financial Results

    PLANEGG and MUNICH, GERMANY / ACCESSWIRE / August 1, 2018 / The Company has further advanced its pipeline, including proprietary and partnered programs, and established a U.S. footprint to prepare for ...

  • ACCESSWIRE4 months ago

    MorphoSys to Host Q2 2018 Conference Call on August 2, 2018

    PLANEGG and MUNICH, GERMANY / ACCESSWIRE / July 25, 2018 / MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC PINK: MPSYF; NASDAQ: MOR) will publish its first six months' 2018 results on August ...

  • ACCESSWIRE4 months ago

    MorphoSys Announces Appointment of Jennifer Herron as President of MorphoSys US Inc. and Executive Vice President, Global Commercial

    Ms. Herron was also appointed as member of the Board of Directors of MorphoSys US Inc. In this newly created role, Ms. Herron will lead the build of MorphoSys's U.S. subsidiary with a focus on establishing the Company's commercial capabilities in the U.S. While the MorphoSys corporate headquarters will remain in Planegg near Munich, Germany, the MorphoSys US Inc. operations, which will be located in New Jersey, will establish a strong U.S. footprint in preparation for the planned commercialization of MOR208. "I am delighted to welcome Jennifer Herron to MorphoSys US Inc.," commented Dr. Simon Moroney, Chief Executive Officer of MorphoSys AG and Chairman of the Board of Directors of MorphoSys US Inc. "Jennifer brings an impressive range of marketing and commercial expertise across multiple therapeutic areas, particularly in oncology.

  • ACCESSWIRE4 months ago

    MorphoSys and Galapagos Sign Global License Agreement for MOR106 with Pharma Partner

    PLANEGG/MUNICH, GERMANY and MECHELEN, BELGIUM / ACCESSWIRE / July 19, 2018 / MorphoSys AG (MOR) (MOR) (MOR.DE) and Galapagos NV (GLPG) announced today that they have entered into a worldwide, exclusive agreement with Novartis Pharma AG covering the development and commercialization of their joint program MOR106. MOR106 is an investigational, fully human, IgG1 monoclonal antibody directed against the target IL-17C that was generated in a collaboration between MorphoSys and Galapagos.

  • ACCESSWIRE4 months ago

    Ad hoc: MorphoSys and Galapagos Sign Global License Agreement for MOR106 with Novartis and MorphoSys Increases its Financial Guidance for 2018

    PLANEGG/MUNICH, GERMANY and MECHELEN, BELGIUM / ACCESSWIRE / July 19, 2018 / MorphoSys AG (MOR), (MOR), (MOR.DE) announces today that MorphoSys and Galapagos NV have entered into a worldwide, exclusive agreement with Novartis Pharma AG covering the development and commercialization of their joint program MOR106. MorphoSys furthermore announces that, in consequence of this agreement with Galapagos and Novartis, it increases its financial guidance for the year 2018 pending clearance by the U.S. antitrust authorities under the Hart-Scott-Rodino Act. MOR106 is an investigational, fully human, IgG1 monoclonal antibody directed against the target IL-17C that was generated in a collaboration between MorphoSys and Galapagos.

  • ACCESSWIRE4 months ago

    MorphoSys Announces its Licensee Janssen has Initiated a Phase 2/3 Program (GALAXI) to Evaluate Tremfya(R) (Guselkumab) in Crohn's Disease

    PLANEGG and MUNICH, GERMANY / ACCESSWIRE / July 10, 2018 / MorphoSys AG (MOR), (MOR), (MOR.DE) announced today that its licensee Janssen Research & Development, LLC, part of the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen), has initiated a pivotal phase 2/3 clinical program to evaluate the efficacy and safety of Tremfya(R) (guselkumab) in the treatment of patients with moderately to severely active Crohn's disease. Expected to enroll approximately 2,000 patients, the program, which is named GALAXI, consists of three separate studies, a phase 2 study (GALAXI 1), followed by two phase 3 studies (GALAXI 2 and GALAXI 3). Tremfya(R) is a fully human anti-IL-23 monoclonal antibody developed by Janssen, and was generated utilizing MorphoSys's proprietary HuCAL antibody technology.

  • ACCESSWIRE5 months ago

    MorphoSys Presents Clinical Data with Blood Cancer Candidate MOR208 in Chronic Lymphocytic Leukemia at EHA 2018 Conference

    PLANEGG and MUNICH, GERMANY / ACCESSWIRE / June 15, 2018 / MorphoSys AG (NASDAQ: MOR), (FSE: MOR), (XETRA: MOR) today announced the presentation of clinical data from the exploratory phase 2 COSMOS trial. ...

  • ACCESSWIRE5 months ago

    MorphoSys Presents Updated Clinical Data for Anti-CD38 Antibody MOR202 in Multiple Myeloma at EHA 2018

    PLANEGG and MUNICH, GERMANY / ACCESSWIRE / June 15, 2018 / MorphoSys AG (MOR), (MOR), (MOR.DE) today presented updated data from the ongoing phase 1/2a study of the anti-CD38 antibody MOR202 in relapsed/refractory multiple myeloma at the European Hematology Association (EHA) Annual Meeting 2018 in Stockholm. The dose escalation trial comprises three arms: MOR202, MOR202 in combination with the immunomodulatory drug (IMiD) lenalidomide (LEN), and MOR202 in combination with the IMiD pomalidomide (POM), in each case with low-dose dexamethasone (DEX). "We are optimistic about the responses seen in patients with multiple myeloma treated with MOR202 plus LEN/DEX and POM/DEX based on matured data as well as about the low proportion of patients experiencing infusion-related reactions," commented Dr. Malte Peters, Chief Development Officer of MorphoSys AG.

  • ACCESSWIRE5 months ago

    New Phase 3 Clinical Trials by MorphoSys's Partner with Gantenerumab in Early Alzheimer's Disease now Underway

    PLANEGG and MUNICH, GERMANY / ACCESSWIRE / June 12, 2018 / MorphoSys AG (NASDAQ: MOR, OTC PINK: MPSYY, FSE: MOR, XETRA: MOR, Prime Standard Segment, TecDAX) announced today that the first patient has been enrolled in a new phase 3 trial of gantenerumab in patients with early Alzheimer's disease. Gantenerumab is a monoclonal antibody directed against amyloid-beta generated by MorphoSys using its proprietary HuCAL antibody technology. Roche is fully responsible for the clinical development of gantenerumab.